Three Biotech Innovators: iBio, Nektar, and Immunic Poised for Market-Moving News

June 24, 2025

DENVER, Colo., Jun 24, 2025 (247marketnews.com)- Three biotech companies, iBio (NASDAQ:IBIO), Nektar Therapeutics (NASDAQ:NKTR), and Immunic (NASDAQ:IMUX), are stepping into the spotlight this week with pivotal updates. From next-generation obesity therapeutics to novel immune modulators and long-term multiple sclerosis data, these companies are delivering the kind of catalysts that often precede sharp market moves.

iBio (IBIO): Expanding the Obesity Pipeline and AstralBio Collaboration

iBio is hosting a major conference call today at 8:30 a.m. ET to unveil its latest preclinical data in obesity and cardiometabolic disease, two of the most high-demand therapeutic areas in biotech today. The company will also announce the third target in its collaboration with AstralBio, joining Myostatin and Activin E.

Led by CEO and CSO Dr. Martin Brenner, iBio is emphasizing next-generation antibody therapeutics, longer-acting, more tolerable, and potentially more durable than current standard-of-care agents. The pipeline includes IBIO-600, a long-acting Myostatin antibody designed to improve lean body mass and metabolic health, and new data on its Activin E program, aimed at regulating energy expenditure.

Dr. Brenner will present “a strategic overview of the obesity strategy,” focusing on how iBio’s AI-powered platform is enabling more precise, patient-tailored antibody designs.

With obesity and cardiometabolic disease representing a multi-billion-dollar market, even preclinical data can have a meaningful impact, particularly as iBio expands its pipeline and attracts potential partnerships.

Nektar Therapeutics (NKTR): Phase 2b Data for Atopic Dermatitis Drug Could Be Pivotal

Nektar will also be in the headlines on June 24 today at 8:15 a.m. ET, when it reports top-line data from the 16-week induction period of its REZOLVE-AD Phase 2b trial for rezpegaldesleukin, a regulatory T-cell (Treg) proliferator being developed for moderate-to-severe atopic dermatitis (AD).

This is a key inflection point for Nektar. Positive results could validate the novel mechanism of expanding Tregs to calm overactive immune responses, a strategy applicable not only to AD but potentially to a broad range of autoimmune diseases.

The company will release a press release with results Tuesday morning, followed by an investor call and webcast. Nektar is under close watch from institutional investors after recent restructuring and data from other immunology assets failed to meet expectations. The REZOLVE-AD data represents a chance to rebuild confidence and potentially re-rate the stock if efficacy and safety signals align.

Immunic (IMUX): Long-Term MS Data Supports Durability and Safety of Vidofludimus Calcium

Immunic recently announced new long-term open-label extension data from its Phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838) in patients with relapsing-remitting multiple sclerosis (RRMS). The numbers are impressive:

  • At week 144, 92.3% of patients remained free of 12-week confirmed disability worsening (CDW)
  • 92.7% remained free of 24-week CDW
  • Safety remains consistent, with no new safety signals emerging even after up to 5.5 years of treatment

The durability data reinforces vidofludimus calcium’s potential as a long-term, oral therapy with disease-modifying benefits. It’s also noteworthy that low discontinuation rates and minimal serious adverse events reflect a favorable tolerability profile—a key differentiator in a crowded MS space.

With over 950 patient-treatment years now documented, the company is building a strong case as it gears up for phase 3 development or potential licensing discussions.

As the biotech sector continues to rotate into high-conviction innovation stories, these three names are worth watching closely. A strong showing from any of them could ignite not just upside in their respective stocks, but renewed interest across the small-cap biotech space more broadly.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (IBIO, NKTR, IMUX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.